login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
APELLIS PHARMACEUTICALS INC (APLS) Stock News
USA
- NASDAQ:APLS -
US03753U1060
-
Common Stock
19.73
USD
-0.37 (-1.84%)
Last: 11/18/2025, 5:20:00 PM
19.73
USD
0 (0%)
After Hours:
11/18/2025, 5:20:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
APLS Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Chartmill
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents an Affordable Growth Opportunity
19 days ago - By: Chartmill
- Mentions:
FMC
FMFC
EBS
GCI
...
These stocks are moving in today's session
6 days ago - By: Benzinga
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
6 days ago - By: Apellis Pharmaceuticals, Inc.
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
6 days ago - By: Apellis Pharmaceuticals, Inc.
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
12 days ago - By: Benzinga
- Mentions:
BJRI
EAT
GLXY
ABVX
This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
13 days ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
13 days ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
18 days ago - By: Zacks Investment Research
- Mentions:
BEAM
FOLD
ANIP
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
19 days ago - By: Chartmill
- Mentions:
FMC
FMFC
EBS
HBIO
...
Here are the top movers in Thursday's session.
19 days ago - By: Chartmill
- Mentions:
FMC
FMFC
EBS
IART
...
The market is filled with gapping stocks in Thursday's session.
19 days ago - By: Zacks Investment Research
Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
19 days ago - By: Chartmill
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Strong Q3 2025 Earnings Beat
20 days ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
20 days ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
a month ago - By: Zacks Investment Research
- Mentions:
RGEN
Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth
a month ago - By: Apellis Pharmaceuticals, Inc.
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
a month ago - By: Apellis Pharmaceuticals, Inc.
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
a month ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
a month ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
3 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
3 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
3 months ago - By: Stocktwits
Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary
4 months ago - By: Yahoo Finance
- Mentions:
NVS
C
NOVN
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target
4 months ago - By: Stocktwits
- Mentions:
GS
MS
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug
Please enable JavaScript to continue using this application.